Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Bladder Cancer Publications

Following is a cumulative list of Hoosier Cancer Research Network publications in bladder cancer.

Manuscripts and Journal Articles

  • NM Hahn, BS Knudsen, S Daneshmand, MO Koch, R Bihrle, RS Foster, TA Gardner, L Cheng, Z Liu, T Breen, MT Fleming, R Lance, CL Corless, AS Alva, SS Shen, F Huang, A Gertych, GE Gallick, J Mallick, C Ryan, MD Galsky, SP Lerner, EM Posadas, G Sonpavde. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Hoosier Cancer Research Network GU07-122. Urol Oncol 2015 Sep 8. pii S1078-1439(15)00402-0. doi: 10.1016/j.urolonc.2015.08.005. [Epub ahead of print] PMID: 26362343
  • Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ. Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU04-75. J Clin Oncol. 2011 Mar 21. [Epub ahead of print] PMID: 21422406
  • CJ Sweeney, BJ Roth, FF Kabbinavar, DJ Vaughn, M Arning, RE Curiel, CK Obasaju, Y Wang, SJ Nichol, DS Kaufman. Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium: Hoosier Oncology Group GU00-13. J Clin Oncol. 2006 Jul 20;24(21):3451-7 PMID: 16849761
  • Jinxing Li, Beth Juliar, Constantin Yiannoutsos, Rafat Ansari, Edward Fox, Michael J. Fisch, Lawrence H. Einhorn, and Christopher J. Sweeney. Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Hoosier Oncology Group Study GU98-2. J Clin Oncol 2005;23 1185-1191 PMID: 15718315

Abstracts, Posters, and Presentations

  • Beatrice Knudsen, Noah M. Hahn, Siamak Daneshmand, Edwin M. Posadas, Sambit Muhanty, Seth P. Lerner, Guru Sonpavde. Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC): Hoosier Oncology Group GU07-122. Accepted to the General Poster Session (Abstract #324) at the 2014 Genitourinary Cancers Symposium, January 30 – February 1, 2014, Orlando FL. J Clin Oncol 32, 2014 (suppl 4; abstr 324)
  • BA Gartrell, NM Hahn, TE Hutson, G Sonpavde, RJ Hauke, A Starodub, AC Small, C-K Tsao, MD Galsky. Phase II trial of gemcitabine and cisplatin plus ipilimumab as first-line treatment for metastatic urothelial carcinoma: Hoosier Oncology Group GU10-148. Accepted as a Poster Presentation at the Trials in Progress Session at the ASCO Annual Meeting, June 1-5, 2012, Chicago, IL. J Clin Oncol 30, 2012 (suppl; abstr TPS4676)
  • N Hahn, S Daneshmand, EM Posadas, MO Koch, R Bihrle, RFoster, TA Masterson, L Cheng, Z Liu, T Breen, MT Fleming, R Lance, CW Ryan, CL Corless, MD Galsky, AS Alva, C Mitchell, SS Shen, SP Lerner, G Sonpavde. A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial. Accepted to the General Poster Session (Abstract #4586) at the ASCO Annual Meeting, June 1-5 2012, Chicago IL. J Clin Oncol 30, 2012 (suppl; abstr 4586)
  • S. Lerner, N.M. Hahn, T. Powles, T. A. Gardner, L. Cheng, J.S. Green, D. M. Berney, D. Taber, J. Hudak, J. Landgraf, S. Shen, G. Sonpavde. A Phase II Trial of Neoadjuvant Cisplatin (C), Gemcitabine (G), and Sunitinib (S) in Muscle-Invasive Urothelial Carcinoma (miUC): Results from Hoosier Oncology Group GU07-123 Trial. Accepted as abstract at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr e15173)
  • N. M. Hahn, W. M. Stadler, R. Zon, D. M. Waterhouse, J. Picus, S. R. Nattam, C. S. Johnson, S. M. Perkins, M. J. Waddell, C. Sweeney. Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). Accepted as a poster discussion at the ASCO annual meeting June 4-8, 2010, Chicago IL J Clin Oncol 28:15s, 2010 (suppl; abstr 4541)
  • N.M. Hahn, W.M. Stadler, R.T. Zon, D. Waterhouse, J. Picus, S. Nattam, C.S. Johnson, S.M. Perkins, C.J. Sweeney. A Multicenter Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) As First-Line Chemotherapy for Metastatic Urothelial Carcinoma (UC); Hoosier Oncology Group GU04-75. Accepted as an oral presentation at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL. J Clin Oncol 27:15s, 2009 (suppl; abstr 5018)
  • Christopher J. Sweeney, Bruce J. Roth, Donald S. Kaufman, Steven J. Nicol A Phase II Study of ALIMTA in Patients with Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium): A Hoosier Oncology Group Study GU00-13. Accepted as a poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL
  • Jinxing Li MD, Beth Juliar MA MS, Rafat Ansari MD, Edward Fox MD, Michael Fisch MD, Lawrence Einhorn MD, Christopher Sweeney MD. A Phase II Study of Weekly Paclitaxel (P) and Gemcitabine (G) in Advanced Transitional Cell Carcinoma (TCC) of the Urothelium): A Hoosier Oncology Group Study GU98-2. Accepted as a poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL
  • R. Parameswaran, Indiana University, Walther Cancer Institute, M. Fisch, M.D.Anderson Cancer Center, Walther Cancer Institute, C. Sweeney, L. Einhorn, Indiana University, Walther Cancer Institute. A Hoosier Oncology Group Phase II Study of Weekly Paclitaxel and Gemcitabine in Advanced Transitional Cell Carcinoma (TCC) of the Bladder: GU98-2. Accepted as a poster presentation for ASCO annual meeting May 12-15, 2001, San Francisco, CA.